LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Amgen Inc. (“Amgen” or the “Company”) (Nasdaq: AMGN) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at firstname.lastname@example.org.
On May 22, 2017, Amgen revealed that its osteoporosis medicine, Evenity, raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by the Company, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, than those who took an older approved medicine.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.